Citations

Clear

6274 citation(s) found for "To, Andrew".

Clinical role of ambulatory reflux monitoring in PPI non‐responders: recommendation statements
Yadlapati, Rena , Gawron, Andrew J. , Gyawali, C. Prakash , Chen, Joan W. , Clarke, John O. , Jain, Anand , Lynch, Kristle L. , Khan, Abraham, Katz, Philip O. , Katzka, David A. , Richter, Joel E. , Schnoll‐Sussman, Felice , Vaezi, Michael F. , Vela, Marcelo F. , Pandolfino, John E. , Chen, Joan , Katzka, D A , Richter, Joel , Vela, Marcelo, Clarke, J , Gyawali, C P , Fass, Ronnie , Khan, Abraham, Spechler, Stuart Jon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 16, 2022 | Volume: 56 | Issue: 8 | Pages: 1274-1283

10.1111/apt.17180 | PMID 35971888 Get It

Summary Background Optimal ambulatory reflux monitoring methodology in symptomatic reflux patients continues to be debated. Aims To utilise published literature and expert opinion to develop recommendation statements addressing use of ambulatory reflux monitoring in clinical practice Methods The RAND Appropriateness Method (RAM) was utilised among 17 experts with discussion, revision and two rounds of ranking of recommendation statements. Ambulatory reflux monitoring protocol, methodology and thresholds ranked as appropriate by ≥80% of panellists met the criteria for appropriateness. Results Prolonged (96‐h recommended) wireless pH monitoring off proton pump inhibitor (PPI) was identified as the appropriate diagnostic tool to assess the need for acid suppression in patients with unproven gastro‐oesophageal reflux disease (GERD) and persisting typical reflux symptoms despite once‐daily PPI. Acid exposure time (AET) <4.0% on all days of monitoring with negative reflux‐symptom association excludes GERD and does not support ongoing PPI treatment. Conversely, AET >6.0% across ≥2 days is conclusive evidence for GERD and supports treatment for GERD, while AET >10% across ≥2 days identifies severe acid burden that supports escalation of anti‐reflux treatment. In previously proven GERD, impedance‐pH monitoring on PPI is helpful in defining refractory GERD and mechanisms of continued symptoms; the presence of <40 reflux events, AET <2.0% and a negative reflux‐symptom association does not support escalation of anti‐reflux treatment. In contrast, AET > 4.0% and positive reflux‐symptom association support escalation of anti‐reflux treatment, including use of invasive therapeutics. Conclusions Statements meeting appropriateness for average clinical care have been identified when utilising reflux monitoring in patients with typical reflux symptoms and PPI non‐response.
Vascular Implications of COVID-19: Role of Radiological Imaging, Artificial Intelligence, and Tissue Characterization: A Special Report
Khanna, Narendra N. , Maindarkar, Mahesh , Paul, Sudip , Bhagawati, Mrinalini , Ahluwalia, Puneet , Ruzsa, Zoltán , Munjral, Smiksha , Krishnan, Padukone R., Singh, Inder M. , Laird, John R. , Fatemi, Mostafa , Dhanjil, Surinder, Saba, Luca , Balestrieri, Antonella , Faa, Gavino , Paraskevas, Kosmas I. , Misra, Durga Prasanna , Agarwal, Vikas , Sharma, Aman , Teji, Jagjit S. , Al-Maini, Mustafa , Rathore, Vijay , Naidu, Subbaram, Liblik, Kiera , Johri, Amer M. , Turk, Monika, Sobel, David , Pareek, Gyan , Miner, Martin , Višković, Klaudija , Tsoulfas, George, Protogerou, Athanase D. , Mavrogeni, Sophie , Fouda, Mostafa M. , Kalra, Manudeep, Suri, Jasjit S. , Paul, Sudip , Bhagawati, Mrinalini , Ruzsa, Zoltan , Munjral, Smiksha , Fatemi, Mostafa , Faa, Gavino , Paraskevas, Kosmas I , Agarwal, Vikas , Tsoulfas, George , Protogerou, Athanasios , Mavrogeni, Sophie , Fouda, Mostafa M , Misra, Durga Prasanna , Naidu, Subbaram , Maindarkar, Mahesh A , Puvvula, Anudeep , Sharma, Aditya , Kolluri, Raghu , Alizad, Azra , Nicolaides, Andrew , Kitas, George D. , Suri, Jasjit S.

Mayo Clinic

Journal of Cardiovascular Development and Disease | August 15, 2022 | Volume: 9 | Issue: 8 | Pages: 268

10.3390/jcdd9080268 | PMID 36005433 Get It

The SARS-CoV-2 virus has caused a pandemic, infecting nearly 80 million people worldwide, with mortality exceeding six million. The average survival span is just 14 days from the time the symptoms become aggressive. The present study delineates the deep-driven vascular damage in the pulmonary, renal, coronary, and carotid vessels due to SARS-CoV-2. This special report addresses an important gap in the literature in understanding (i) the pathophysiology of vascular damage and the role of medical imaging in the visualization of the damage caused by SARS-CoV-2, and (ii) further understanding the severity of COVID-19 using artificial intelligence (AI)-based tissue characterization (TC). PRISMA was used to select 296 studies for AI-based TC. Radiological imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound were selected for imaging of the vasculature infected by COVID-19. Four kinds of hypotheses are presented for showing the vascular damage in radiological images due to COVID-19. Three kinds of AI models, namely, machine learning, deep learning, and transfer learning, are used for TC. Further, the study presents recommendations for improving AI-based architectures for vascular studies. We conclude that the process of vascular damage due to COVID-19 has similarities across vessel types, even though it results in multi-organ dysfunction. Although the mortality rate is ~2% of those infected, the long-term effect of COVID-19 needs monitoring to avoid deaths. AI seems to be penetrating the health care industry at warp speed, and we expect to see an emerging role in patient care, reduce the mortality and morbidity rate.
Outcomes after repeat hepatectomy for colorectal liver metastases from the colorectal liver operative metastasis international collaborative (COLOMIC)
Valenzuela, Cristian D. , Moaven, Omeed , Gawdi, Rohin , Piccolo, Nico R. Del, Cheung, Tan To, Corvera, Carlos U. , Wisneski, Andrew D. , Zarandi, Nima Pourhabibi , Dourado, Justin , Perry, Kathleen C., Shen, Perry , Del Piccolo, Nico R, Moaven, Omeed , Stauffer, John , Cheung, Tan To, Cha, Charles , Russell, Gregory B.

Mayo Clinic

Journal of Surgical Oncology | August 15, 2022 | Volume: 126 | Issue: 7 | Pages: 1242-1252

10.1002/jso.27056 | PMID 35969175 Get It

AbstractBackgroundResection of colorectal liver metastasis (CLM) is beneficial when feasible. However, the benefit of second hepatectomy for hepatic recurrence in CLM remains unclear.MethodsThe Colorectal Liver Operative Metastasis International Collaborative retrospectively examined 1004 CLM cases from 2000 to 2018 from a total of 953 patients. Hepatic recurrence after initial hepatectomy was identified in 218 patients. Kaplan–Meier analysis was performed for overall survival (OS) and recurrence‐free survival (RFS). Propensity score matching (PSM) was performed to offset selection bias. Cox proportional‐hazards regression was performed to identify risk factors associated with OS.ResultsA total of 51 patients underwent second hepatectomy. Unadjusted median OS was 60.1 months in repeat‐hepatectomy versus 38.3 months in the single‐hepatectomy group (p = 0.015). In the PSM population, median OS remained significantly better in the repeat‐hepatectomy group (60.1 vs. 33.1 months; p = 0.0023); median RFS was 12.4 months for the repeat‐hepatectomy group, versus 9.8 months in the single‐hepatectomy group (p = 0.0050). Repeat hepatectomy was associated with lower risk of death (hazard ratio: 0.283; p = 0.000012). Obesity, tobacco use, and high intraoperative blood loss were associated with significant risk of death (p < 0.05).ConclusionIn CLM with hepatic recurrence, second hepatectomy was beneficial for OS. With PSM, the OS benefit of performing a second hepatectomy remained significant.
Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics
Hinson, Shannon R., Honorat, Josephe A., Grund, Ethan M. , Clarkson, Benjamin D. , Miske, Ramona , Scharf, Madeleine, Zivelonghi, Cecilia , Al‐Lozi, Muhammad, Bucelli, Robert C. , Cho, Tracey , Grell, Jacquelyn A., López‐Chiriboga, A. Sebastian , Levin, Marc S., Merati, Melody, Montalvo, Mayra , Pittock, Sean J. , Wilson, Michael R. , Howe, Charles L. , Budhram, Adrian , Grell, Jacquelyn, Lopez-Chiriboga, A Sebastian , Pittock, S J , Wilson, Michael R , McKeon, Andrew , Howe, Charles L , Cho, Tracey A , Choi, Ellie, Levin, Marc, McKeon, Andrew

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1090-1101

10.1002/ana.26482 | PMID 36053822 Get It

Background and ObjectivesWe sought to determine clinical significance of neuronal septin autoimmunity and evaluate for potential IgG effects.MethodsSeptin‐IgGs were detected by indirect immunofluorescence assays (IFAs; mouse tissue and cell based) or Western blot. IgG binding to (and internalization of) extracellular septin epitopes were evaluated for by live rat hippocampal neuron assay. The impact of purified patient IgGs on murine cortical neuron function was determined by recording extracellular field potentials in a multielectrode array platform.ResultsSeptin‐IgGs were identified in 23 patients. All 8 patients with septin‐5‐IgG detected had cerebellar ataxia, and 7 had prominent eye movement disorders. One of 2 patients with co‐existing septin‐7‐IgG had additional psychiatric phenotype (apathy, emotional blunting, and poor insight). Fifteen patients had septin‐7 autoimmunity, without septin‐5‐IgG detected. Disorders included encephalopathy (11; 2 patients with accompanying myelopathy, and 2 were relapsing), myelopathy (3), and episodic ataxia (1). Psychiatric symptoms (≥1 of agitation, apathy, catatonia, disorganized thinking, and paranoia) were prominent in 6 of 11 patients with encephalopathic symptoms. Eight of 10 patients with data available (from 23 total) improved after immunotherapy, and a further 2 patients improved spontaneously. Staining of plasma membranes of live hippocampal neurons produced by patient IgGs (subclasses 1 and 2) colocalized with pre‐ and post‐synaptic markers. Decreased spiking and bursting behavior in mixed cultures of murine glutamatergic and GABAergic cortical neurons produced by patient IgGs were attributable to neither antigenic crosslinking and internalization nor complement activation.InterpretationSeptin‐IgGs are predictive of distinct treatment‐responsive autoimmune central nervous system (CNS) disorders. Live neuron binding and induced electrophysiologic effects by patient IgGs may support septin‐specific pathophysiology. ANN NEUROL 2022;92:1090–1101
Relations of Current and Past Cancer with Severe Outcomes among 104,590 Hospitalized COVID-19 Patients: The COVID EHR Cohort at the University of Wisconsin
Piasecki, Thomas M. , Smith, Stevens S. , Baker, Timothy B. , Fiore, Michael C. , Adsit, Robert T. , Bolt, Daniel M. , Conner, Karen L. , Bernstein, Steven L. , Eng, Oliver S. , Lazuk, David , Gonzalez, Alec , Hayes-Birchler, Todd , Jorenby, Douglas E. , D’Angelo, Heather , Kirsch, Julie A. , Williams, Brian , Kent, Sean , Kim, Hanna , Lubanski, Stanley A. , Cai, Yuxin , Kashyap, Nitu , Mathew, Jomol , McMahan, Gabriel , Rolland, Betsy , Tindle, Hilary A. , Warren, Graham , Abu-el-rub, Noor , An, Lawrence C. , Boyd, Andrew D. , Brunzell, Darlene H., Carrillo, Victor A. , Chen, Li‐Shiun , Davis, James M. , Deshmukh, Vikrant , Dilip, Deepika , Ha, Patrick K. , Jose, Thulasee , Klass, Elizabeth , Lui, Michelle , Poon, Chester , Tong, Elisa K. , Wilson, Karen M. , Theobald, Wendy E. , Nolan, Margaret B , Piasecki, Thomas M , Smith, Stevens S , Baker, Timothy B , Fiore, Michael C , Adsit, Robert T , Bolt, Daniel M , Conner, Karen L , Bernstein, Steven L , Eng, Oliver , Lazuk, David , Gonzalez, Alec , Hayes-Birchler, Todd , Jorenby, Douglas E , D'Angelo, Heather , Kirsch, Julie A , Williams, Brian S , Kent, Sean , Kim, Hanna , Lubanski, Stanley A , Yu, Menggang , Suk, Youmi , Cai, Yuxin , Kashyap, Nitu , Mathew, Jomol , McMahan, Gabriel , Rolland, Betsy , Tindle, Hilary A , Warren, Graham W , Abu-El-Rub, Noor , An, Lawrence C , Boyd, Andrew D , Carrillo, Victor A , Chen, Li-Shiun , Davis, James M , Deshmukh, Vikrant G , Dilip, Deepika , Goldstein, Adam O , Ha, Patrick K , Iturrate, Eduardo , Jose, Thulasee , Khanna, Niharika , King, Andrea , Klass, Elizabeth , Lui, Michelle , Mermelstein, Robin J , Poon, Chester , Tong, Elisa , Wilson, Karen M , Theobald, Wendy E , Slutske, Wendy S , Nolan, Margaret , Yu, Menggang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 15, 2022 | Volume: 32 | Issue: 1 | Pages: 12-21

10.1158/1055-9965.epi-22-0500 | PMID 35965473 Get It

Abstract Background: There is mixed evidence about the relations of current versus past cancer with severe COVID-19 outcomes and how they vary by patient and cancer characteristics. Methods: Electronic health record data of 104,590 adult hospitalized patients with COVID-19 were obtained from 21 United States health systems from February 2020 through September 2021. In-hospital mortality and ICU admission were predicted from current and past cancer diagnoses. Moderation by patient characteristics, vaccination status, cancer type, and year of the pandemic was examined. Results: 6.8% of the patients had current (n = 7,141) and 6.5% had past (n = 6,749) cancer diagnoses. Current cancer predicted both severe outcomes but past cancer did not; adjusted odds ratios (aOR) for mortality were 1.58 [95% confidence interval (CI), 1.46–1.70] and 1.04 (95% CI, 0.96–1.13), respectively. Mortality rates decreased over the pandemic but the incremental risk of current cancer persisted, with the increment being larger among younger vs. older patients. Prior COVID-19 vaccination reduced mortality generally and among those with current cancer (aOR, 0.69; 95% CI, 0.53–0.90). Conclusions: Current cancer, especially among younger patients, posed a substantially increased risk for death and ICU admission among patients with COVID-19; prior COVID-19 vaccination mitigated the risk associated with current cancer. Past history of cancer was not associated with higher risks for severe COVID-19 outcomes for most cancer types. Impact: This study clarifies the characteristics that modify the risk associated with cancer on severe COVID-19 outcomes across the first 20 months of the COVID-19 pandemic. See related commentary by Egan et al., p. 3
EFFECT OF PHYSICIAN FACE MASK USE ON POSTINJECTION ENDOPHTHALMITIS
Fortes, Blake H. , Astafurov, Konstantin , Hodge, David O. , Smith, Wendy M. , Olsen, Timothy W. , Iezzi, Raymond , Bakri, Sophie J. , Astafurov, Konstantin V, Barkmeier, Andrew J. , Fortes, Blake H

Mayo Clinic

Retina | August 13, 2022 | Volume: 42 | Issue: 11 | Pages: 2120-2127

10.1097/iae.0000000000003592 | PMID 35963006 Get It

Purpose: To examine the impact of physician face mask use on the rates and outcomes of postinjection endophthalmitis. Methods: A multicenter retrospective, comparative cohort study comparing endophthalmitis rate and visual acuity of eyes that developed endophthalmitis after antivascular endothelial growth factor injections at Mayo Clinic Rochester (MCR) and at Mayo Clinic Health System sites depending on physician masking. Results: A total of 164,824 injections were performed at MCR and Mayo Clinic Health System sites. Of these, 66,098 injections were in the no mask group and 98,726 injections were in the mask group. Overall, there were no differences in the rates of infectious endophthalmitis in the no mask versus mask cohorts (overall: no mask: 20 cases [0.0303%] vs. mask: 41 cases (0.0415%); P = 0.24; infectious: no mask: 12 cases [0.018%] versus mask: 13 cases [0.0132%]; P = 0.42). At MCR alone, there was a significant reduction in infectious endophthalmitis between the no mask versus mask groups (no mask: 9 cases [0.0297%] versus mask: 2 cases [0.003%]; P < 0.001). Only 2 cases of infectious endophthalmitis occurred at MCR after the face mask policy was implemented (1 in 30,000 injections). At presentation and at 6 months, the average visual acuity was similar for patients who developed endophthalmitis between the no mask versus mask groups. Conclusion: Physician face mask use did not affect the rate or outcome of postinjection endophthalmitis. However, there was a significant reduction at MCR after masking along with other quality improvement measures, including performance of injections in a dedicated procedure room and preparation of patients by nurses, that led to a low rate of endophthalmitis.
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, Robert I. , Bischoff, Lindsay , Ball, Douglas W., Bernet, Victor , Blomain, Erik , Busaidy, Naifa L. , Campbell, Michael J. , Dickson, Paxton V. , Ehya, Hormoz, Guo, Theresa , Holt, Shelby , Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Mandel, Susan J., McIver, Bryan, Raeburn, Christopher D., Rezaee, Rod , Roth, Mara Y. , Scheri, Randall P., Sipos, Jennifer A. , Wang, Thomas N., Wirth, Lori J. , Cassara, Carly J., Darlow, Susan, Haddad, Robert , Duh, Quan‐Yang , Goldner, Whitney Sears , Haymart, Megan R. , Iagaru, Andrei H. , Markovina, Stephanie T. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 925-951

10.6004/jnccn.2022.0040 | PMID 35948029 Get It

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
Change in Body Mass Index and Attributable Risk of New-Onset Hypertension Among Obese Living Kidney Donors
Reed, Rhiannon D. , McLeod, M. Chandler, MacLennan, Paul A. , Pittman, Sydney E., Maynor, Andrew G., Stanford, Luke A., Baker, Gavin , Silkensen, John R., Segev, Dorry L. , Lewis, Cora E. , Segev, Dorry L , Kumar, Vineeta , Schinstock, Carrie A. , Roll, Garrett Richard , Orandi, Babak John , Locke, Jayme E.

Mayo Clinic

Annals of Surgery | August 10, 2022 | Volume: 278 | Issue: 1 | Pages: e115-e122

10.1097/sla.0000000000005669 | PMID 35946818 Get It

Objective: To examine whether body mass index (BMI) changes modify the association between kidney donation and incident hypertension. Background: Obesity increases hypertension risk in both general and living kidney donor (LKD) populations. Donation-attributable risk in the context of obesity, and whether weight change modifies that risk, is unknown. Methods: Nested case-control study among 1558 adult LKDs (1976–2020) with obesity (median follow-up: 3.6 years; interquartile range: 2.0–9.4) and 3783 adults with obesity in the Coronary Artery Risk Development in Young Adults (CARDIA) and Atherosclerosis Risk in Communities (ARIC) studies (9.2 y; interquartile range: 5.3–15.8). Hypertension incidence was compared by donor status using conditional logistic regression, with BMI change investigated for effect modification. Results: Overall, LKDs and nondonors had similar hypertension incidence [incidence rate ratio (IRR): 1.16, 95% confidence interval (95% CI): 0.94–1.43, P=0.16], even after adjusting for BMI change (IRR: 1.25, 95% CI: 0.99–1.58, P=0.05). Although LKDs and nondonors who lost >5% BMI had comparable hypertension incidence (IRR: 0.78, 95% CI: 0.46–1.34, P=0.36), there was a significant interaction between donor and >5% BMI gain (multiplicative interaction IRR: 1.62, 95% CI: 1.15–2.29, P=0.006; relative excess risk due to interaction: 0.90, 95% CI: 0.24–1.56, P=0.007), such that LKDs who gained weight had higher hypertension incidence than similar nondonors (IRR: 1.83, 95% CI: 1.32–2.53, P<0.001). Conclusions: Overall, LKDs and nondonors with obesity had similar hypertension incidence. Weight stability and loss were associated with similar hypertension incidence by donor status. However, LKDs who gained >5% saw increased hypertension incidence versus similar nondonors, providing support for counseling potential LKDs with obesity on weight management postdonation.
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Brown, Justin C. , Ma, Chao , Shi, Qian , Fuchs, Charles S. , Niedzwiecki, Donna , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Lewis, DeQuincy Andrew, Krishnamurthi, Smitha , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Brown, Justin C. , Kuebler, J. Philip , Niedzwiecki, Donna , Kumar, Pankaj , Krishnamurthi, Smitha , O'Reilly, Eileen M , Shields, Anthony F , Meyerhardt, Jeffrey A , Brown, Justin C , Shi, Qian , Meyer, Jeffrey , Zemla, Tyler , Tan, Benjamin, O’Reilly, Eileen M. , Brown, Justin C.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2022 | Volume: 41 | Issue: 2 | Pages: 243-254

10.1200/jco.22.00171 | PMID 35944235 Get It

PURPOSE To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer. METHODS We conducted a prospective cohort study nested within a randomized multicenter trial of stage III colon cancer that compared 3 versus 6 months of fluorouracil, leucovorin, and oxaliplatin with or without celecoxib. We measured recreational physical activity in the first 3 months of chemotherapy and again 6 months after completion of chemotherapy. The primary end point was DFS. RESULTS During a median follow-up of 5.9 years, 457 of 1,696 patients experienced disease recurrence or death. For total recreational physical activity volume, the 3-year DFS was 76.5% with < 3.0 metabolic equivalent task hours per week (MET-h/wk) and 87.1% with ≥ 18.0 MET-h/wk (risk difference [RD], 10.6%; 95% CI, 4.7 to 19.4; P < .001). For light-intensity to moderate-intensity activities, the 3-year DFS was 65.7% with 0.0 h/wk and 87.1% with ≥ 1.5 h/wk (RD, 21.4%; 95% CI, 9.2 to 37.1; P < .001). For vigorous-intensity activity, the 3-year DFS was 76.0% with 0.0 h/wk and 86.0% with ≥ 1.0 h/wk (RD, 10.0%; 95% CI, 4.5 to 18.9; P < .001). For brisk walking, the 3-year DFS was 81.7% with < 1.0 h/wk and 88.4% with ≥ 3.0 h/wk (RD, 6.7%; 95% CI, 3.0 to 13.8; P < .001). For muscle strengthening activity, the 3-year DFS was 81.8% with 0.0 h/wk and 88.8% for ≥ 0.5 h/wk (RD, 7.0%; 95% CI, 3.1 to 14.2; P = .003). CONCLUSION Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS.